\n\n
Past and present stories of the three drugs
\n\nRemdesivir (GS-5734)
\n\n\n\t- Remdesivir is a new nucleoside-analogue antiviral drug and a broad-spectrum antiviral drug. The nucleoside analogues are an important class of drugs used in clinical treatment of viral infectious diseases, tumors, and AIDS. Nearly 50% of the currently used antiviral drugs are members of the nucleosides.
\n\t- Remdesivir has been used to treat Ebola virus disease and Marburg virus infection. In addition, studies have shown that this drug also shows better antiviral activity against the respiratory syncytial virus, MERS virus, etc., helps repair the damaged lung tissue, and has a better therapeutic effect than combination therapy with lopinavir/ritonavir and interferon beta.
\n\t- The phase III clinical trial of remdesivir for the treatment of Ebola virus infection has been completed with relatively complete human pharmacokinetic and safety data. However, the efficacy and safety of remdesivir in patients infected with 2019-nCov still need to be further confirmed by clinical studies.
\n
\n\n\n\nChloroquine
\n\n\n\t- It has been applied to clinical practice since 1944. It was initially used to treat malaria, and its use continued to expand afterwards. It can also be used to treat hepatic amebiasis, clonorchiasis, lung fluke disease, connective tissue disease, etc.
\n\t- Its principle of treating malaria is to interfere with the DNA replication of schizont of malaria parasites, causing the polypides to die due to lack of amino acids.
\n\t- Side reactions: Appetite loss, nausea, vomiting, diarrhea and other reactions may be seen after medication. Sometimes white blood cell decrease is seen. If the count of white blood cells is less than 4000, the drug should be discontinued.
\n
\n\nLopinavir/ritonavir
\n\n\n\t- They were approved by FDA in 2000 for antiretroviral therapy of AIDS. Both drugs are protease inhibitors, which inhibit the function of proteases mainly by binding to the viral proteases to interfere with the HIV replication.
\n\t- The coronavirus replication also requires the action of viral proteases. If protease inhibitors, such as lopinavir/ritonavir, can also bind to coronavirus proteases to inhibit their normal function, they can play a role in preventing coronavirus. Previous in vitro studies have shown that lopinavir/ritonavir can inhibit the replication of MERS-CoV (a type of coronavirus) and SARS-CoV (a type of coronavirus).
\n
',recruit_treatment:[],summary_url:e,thanks:[],diseases:[],releasetime:"2021-09-16",op_sole:0,op_author:{op_doctor:[{prefix:e,weight:0,follow:0,sole:0,department:e,drid:15439,name:a,hprank:e,text:o,hpid:0,icon:e,position:e,hospital:e,doctor_type:1,doctor_clickable:0,hospital_clickable:0}],op_hospital:{hpid:0,icon:e,info:e,prefix:e,hprank:e,clickable:0,name:e}},title:"Existing Drugs May Come in Handy to Treat COVID-19",docid:t,info_type:0,copyright_head:e,op_keyword:[],url:e,ctype:1,source:e,ref_info:["Chan JF, Yao Y,Yeung ML,et al. Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset[J]. J Infect Dis,2015 (212):1904-1913.","Chu CM,Cheng VCC,Hung IFN,et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J]. Thorax,2004 (59):252-256.","de Wilde AH,Snijder EJ,Kikkert M,et al. Host Factors in Coronavirus Replication[J]. Curr Top Microbiol Immunol,2018 (419):1-42.","Brown AJ,Won JJ,Graham RL,et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase[J]. Antiviral Res,2019 (169):104541.","Jordan PC,Stevens SK,Deval J. Nucleosides for the treatment of respiratory RNA virus infections[J]. Antivir Chem Chemother,2018 (26):2040206618764483.","Sheahan TP,Sims AC,Leist SR,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun,2020 (11):222.","Mair-Jenkins J,Saavedra-Campos M,Baillie JK,et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis[J]. J Infect Dis,2015 (211):80-90."],op_doctors:[],ref:[],embedVideoId:[],tname:n,authorInfo:{doctors:[{prefix:e,weight:0,follow:0,sole:0,department:e,drid:15439,name:a,hprank:e,text:o,hpid:0,icon:"https://th-yidian-cos-1251316161.file.myqcloud.com/yidian/production/_xcx/webrebuild/h5-baike/common/comment/avatar-default.jpg",position:e,hospital:e,doctor_type:1,doctor_clickable:0,hospital_clickable:0}],hospital:i}},tname:n,docType:1,diseaseName:e,audioData:i,relatedDocsInfo:[],showFullText:!1,metaDataType:"article",darkModeAdtags:[{adtagName:"sys",mode:1},{adtagName:"jingxun.nr.wz.ss",mode:1},{adtagName:"jingxun.nr.vd.ss",mode:1},{adtagName:"jingxun.bk.jb.ss",mode:1},{adtagName:"jingxun.bk.zz.ss",mode:1},{adtagName:"jingxun.bk.sscz.ss",mode:1},{adtagName:"jingxun.bk.jczb.ss",mode:1},{adtagName:"jingxun.bk.xytym.ss",mode:1},{adtagName:"jingxun.bk.xyhxcf.ss",mode:1},{adtagName:"jingxun.bk.zytym.ss",mode:1},{adtagName:"jingxun.bk.zyspm.ss",mode:1},{adtagName:"jingxun.bk.yxmc.ss",mode:1},{adtagName:"jingxun.bk.jj.ss",mode:1},{adtagName:"huawei.push",mode:1}],sourceid:4}],fetch:{},error:i,state:{searcher:e,footer:e,modal:e,topTip:e,focus:!1,getScore:!1,message:{redpointSwitch:!0,redpointNotifySwitch:!0,redpointState:{},redpointNotifyState:{6:0},msgerList:[],msgList:{},tanyiList:[],newStatus:{7:0,8:0,9:0,10:0,11:0}},globalPlugin:{showReviewDoctorGuide:{docid:e,visible:!1},showSearchRecommend:!1}},serverRendered:!0,routePath:"/mobile/article.html",config:{app:{basePath:"/",assetsPath:"/",cdnURL:"//staticb.baike.qq.com/yidian/production/_nuxt/"}}}}("",null,"tx00002001oyd7wu","Tencent Medipedia","Tencent Medipedia审阅","文章详情")